


# OIRM IMPACTS

Your imagination. OIRM's expertise. Our future. | [www.oirm.ca](http://www.oirm.ca)



## Our researchers collaborate across 9 Ontario cities

\*includes stem cell biologists, clinicians, bioengineers and other scientists along with 1700+ trainees and staff



## OUR VISION



OIRM is working to revolutionize the treatment of degenerative diseases, making Ontario a global leader in the development and commercialization of stem cell-based products and therapies.



*OIRM's support has been critical to my heart repair research and in leveraging this work into new business and health opportunities for Ontarians.*



- Michael Laflamme, OIRM PI, University Health Network

## IN PROFILE

### Disease Team Grant (value \$1.85M; 2015-2017)

**Lead Investigator:** Dr. Michael Laflamme, University Health Network

**Project Title:** Heart regeneration with stem cell-derived heart muscle cells

**Disease Target:** Heart failure

This project uses pluripotent stem cells to grow new tissue that can regenerate areas of damage after a heart attack, turning scar tissue back into functioning heart muscle. The preclinical studies from this work are intended to provide the safety and efficacy data required to initiate a first-in-human clinical trial.

## HIGHLIGHT OF THE YEAR

Our investment in heart regeneration through this Disease Team led, in part, to an investment of \$225M by Bayer and Versant Ventures in the creation of BlueRock Therapeutics, a new biotech company to be based in Toronto, New York and Boston. Dr. Laflamme's research is being developed as one of the company's lead offerings.

## OUR RESULTS



OIRM is supporting a multi-centre clinical trial, based in Ottawa, using mesenchymal stem cells for the treatment of septic shock.



Number of Disease Team and Accelerator projects funded in 2016-17, valued at \$5M, in diabetes, immune response, brain, heart, lung, vision and spinal cord repair.



Support for our commercialization partner, CCRM, led to 13 new patent applications, four new licences and three new companies.



Direct audience of more than 100,000 for OIRM events, web, videos and feature articles.



@OIRMnews